Loading…
Ken GriffinHeld
Citadel Advisors · Q2 2026
$8.13K
31.55K shares · 0.0% of portfolio
Accuray Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -95.7% over 5Y.
today you would have $54.46▼ -94.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.22 | $0.82 | $1.98 | $2.83 | $2.09 | $4.77 | $4.17 | $2.82 | $3.41 | $4.30 | $4.60 | $6.75 | $7.55 | $8.70 | $6.43 | $4.23 | $6.75 | |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| FEMYFemasys Inc | $3.20 | — | 2.4x | — | -424.97% | $26.8M |
| BYSIBeyondSpring Inc. | $0.67 | — | — | — | — | $27.36M |
| PLRZPolyrizon Ltd. | $13.15 | — | 1.0x | — | -25.38% | $27.39M |
| LTRNLantern Pharma Inc. | $2.07 | — |
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Company description provided by Yahoo Finance.
| P/E |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 104.3x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 135.0x |
| P/S | 0.9x | 0.1x | 0.2x | 0.4x | 0.6x | 0.5x | 1.1x | 1.0x | 0.6x | 0.7x | 0.9x | 0.9x | 1.4x | 1.6x | 2.1x | 1.1x | 1.3x | 1.8x |
| P/B | 5.1x | 0.6x | 1.1x | 4.4x | 5.1x | 3.7x | 6.3x | 6.0x | 5.0x | 6.1x | 7.7x | 6.3x | 7.1x | 5.9x | 6.1x | 2.3x | 1.2x | 2.4x |
| EPS | -$0.40 | -$0.02 | -$0.16 | -$0.10 | -$0.06 | -$0.07 | $0.04 | -$0.19 | -$0.28 | -$0.36 | -$0.32 | -$0.51 | -$0.47 | -$1.41 | -$1.02 | -$0.44 | $0.05 |
| Profit margin | -5.90% | -12.24% | -0.35% | -3.48% | -2.07% | -1.24% | -1.59% | 1.00% | -3.92% | -5.90% | -7.71% | -6.40% | -10.59% | -9.60% | -36.87% | -19.17% | -12.20% | 1.28% |
| ROE | -34.48% | -117.97% | -1.96% | -34.48% | -17.29% | -10.05% | -9.17% | 6.01% | -32.94% | -49.14% | -63.57% | -42.75% | -53.06% | -35.97% | -109.05% | -38.48% | -11.28% | 1.67% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| -400.92% |
| $26.46M |
| CVMCel Sci Corp | $1.56 | — | 2.5x | — | -252.53% | $27.44M |
| BEATHeartBeam, Inc. | $0.47 | — | 3.2x | — | -328.44% | $26.31M |